ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE Russian patent published in 2022 - IPC C07K16/28 A61K39/395 C12N15/13 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: monoclonal antibody to PD-L1, its antigen-binding fragment, its production method, and its pharmaceutical use, as well as a nucleic acid molecule encoding the monoclonal antibody or its antigen-binding fragment, a recombinant vector, a host cell, a pharmaceutical composition for the treatment of diseases associated with human PD-L1, and a method for the treatment of diseases associated with human PD-L1 are presented.

EFFECT: invention allows for obtaining an antibody to PD-L1 and its antigen-binding fragment, used for the effective treatment of diseases or disorders associated with PD-L1.

14 cl, 5 dwg, 16 tbl, 10 ex